source
- FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissionerThe FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…
- AriBio’s Alzheimer’s trial of repurposed erectile-dysfunction drug shows modest, inconclusive resultsAriBio tested a medication originally approved for erectile dysfunction as a possible therapy for Alzheimer’s disease. The recent Boston‑based study reported only modest signals and failed to show…Endpoints · 23h agoNegative readoutNegative